Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies

Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.